TD Waterhouse Canada Inc. cut its position in shares of CVS Health Corporation (NYSE:CVS – Free Report) by 30.4% in the third quarter, Holdings Channel reports. The institutional investor owned 314,916 shares of the pharmacy operator’s stock after selling 137,572 shares during the period. TD Waterhouse Canada Inc.’s holdings in CVS Health were worth $27,534,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of CVS. Cyndeo Wealth Partners LLC raised its holdings in shares of CVS Health by 17.9% in the third quarter. Cyndeo Wealth Partners LLC now owns 7,764 shares of the pharmacy operator’s stock valued at $665,000 after purchasing an additional 1,180 shares during the last quarter. Pension & Wealth Management Advisors Inc. lifted its position in shares of CVS Health by 405.5% in the third quarter. Pension & Wealth Management Advisors Inc. now owns 1,011 shares of the pharmacy operator’s stock worth $87,000 after purchasing an additional 811 shares in the last quarter. Howard Capital Management LLC lifted its position in shares of CVS Health by 99.9% in the third quarter. Howard Capital Management LLC now owns 18,915 shares of the pharmacy operator’s stock worth $1,621,000 after purchasing an additional 9,451 shares in the last quarter. Annex Advisory Services LLC boosted its holdings in CVS Health by 3.0% during the third quarter. Annex Advisory Services LLC now owns 7,071 shares of the pharmacy operator’s stock worth $606,000 after purchasing an additional 204 shares during the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. boosted its holdings in CVS Health by 2.5% during the third quarter. Cantor Fitzgerald Investment Advisors L.P. now owns 260,592 shares of the pharmacy operator’s stock worth $22,330,000 after purchasing an additional 6,402 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.
CVS Health Stock Down 0.2%
CVS stock opened at $92.41 on Friday. The company has a market cap of $118.19 billion, a price-to-earnings ratio of 24.45, a P/E/G ratio of 0.86 and a beta of 0.60. CVS Health Corporation has a twelve month low of $69.51 and a twelve month high of $110.68. The business has a 50 day moving average price of $91.74 and a two-hundred day moving average price of $93.02. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74.
CVS Health (NYSE:CVS – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%. The company had revenue of $106.10 billion for the quarter, compared to analysts’ expectations of $100.03 billion. During the same quarter in the prior year, the business posted $1.81 EPS. The business’s revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Analysts anticipate that CVS Health Corporation will post 8.02 EPS for the current fiscal year.
CVS Health Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Thursday, October 22nd will be paid a $0.6650 dividend. The ex-dividend date of this dividend is Thursday, October 22nd. This represents a $2.66 annualized dividend and a dividend yield of 2.9%. CVS Health’s dividend payout ratio (DPR) is currently 70.37%.
More CVS Health News
Here are the key news stories impacting CVS Health this week:
- Positive Sentiment: Value and dividend appeal: Zacks identifies CVS as a potentially attractive long-term value stock, while a separate dividend roundup highlights CVS among income-oriented companies. These reports may support investor interest, although they do not represent new company guidance. Why CVS Health Is a Top Value Stock for the Long-Term Dividend roundup
- Positive Sentiment: Care-management and consumer initiatives: CVS Caremark is promoting more connected, personalized pharmacy-benefit experiences. CVS also announced a women’s midlife-health research collaboration and highlighted Signify Health’s at-home heart-rhythm monitoring for eligible members. These efforts could strengthen engagement and differentiate CVS’s health-services platform, but the articles provide no immediate financial targets. CVS Caremark Is Transforming the Health Care Experience CVS Health midlife-health collaboration
- Neutral Sentiment: CVS Caremark appeared in a consumer-focused segment explaining pharmacy benefits as customers evaluate insurance plans. The exposure may improve public understanding of the business but is unlikely to materially affect near-term earnings. CVS Caremark explains pharmacy benefits
- Negative Sentiment: Medicare Advantage exposure: Reports that Medicare Advantage plans, including a CVS plan, will leave New Hampshire raise concerns about membership losses and pressure on the company’s government-business outlook. The specific financial impact was not disclosed. Medical Advantage plans leaving New Hampshire
- Negative Sentiment: Legal overhang: CVS faces a reported $315 million settlement related to allegations involving dangerous opioid prescriptions. Even if the payment is manageable relative to CVS’s size, the matter adds costs and reputational risk. CVS opioid settlement
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on CVS. BMO Capital Markets set a $112.00 target price on shares of CVS Health in a research report on Wednesday, September 9th. Cantor Fitzgerald reiterated a “neutral” rating on shares of CVS Health in a research note on Friday, October 9th. HSBC reissued a “hold” rating and set a $103.00 price target on shares of CVS Health in a research report on Monday, July 6th. Piper Sandler set a $112.00 price objective on shares of CVS Health in a research note on Wednesday, September 9th. Finally, Truist Financial raised their price objective on CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Twenty analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $107.80.
Get Our Latest Stock Analysis on CVS Health
CVS Health Profile
CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.
The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.
Featured Articles
- Five stocks we like better than CVS Health
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS – Free Report).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.
